Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]
(Synonyms: H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH ) 目录号 : GP10141Sequence: H2N-FLDPRPLTV-OH
Sample solution is provided at 25 µL, 10mM.
H2N-FLDPRPLTV-OH
Cytochrome P450 CYP1B1 is a dioxin-inducible form of the cytochrome P450 family of xenobiotic metabolizing enzymes1.
HLA-A2 restricted, CYP1B1 190–198 (CYP190) peptide specific T cell responses are induced in HLA-A2Kb transgenic mice by immunization with ZYC300, a PLG microparticle formulation that contains a plasmid DNA encoding the tumor associated antigen CYP1B12, 3.
Each successive co-application of EPT contributes to an escalating T cell response that can be observed 2 weeks after the last immunization, and that even a single EPT when given with the usually ineffective 30 µg dose of ZYC300 was able to induce a detectable CD8+ CYP190 specific T cell response4.
References:
1. Murray,G.I., Taylor, M. C., et al 1997; Tumor-specific Expression of Cytochrome P450 CYP1B11. Cancer Research. 57:3026-3031.
2. Luby TM, Cole GA, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor associated antigen cytochrome P450 1B1. Clinical Immunology 2004;112(1):45–53.
3. Maecker DH, Sherr RH, Vonderheide MS, von Bergwelt-Baildon MS, Hirano N, Anderson K, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102(9):3287–94.
4. Barbon, C. M., Baker, L et al 2010 In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine; 28:7852-7864
Cas No. | SDF | ||
别名 | H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH | ||
Canonical SMILES | NC(C(NC(CC(C)C)C(NC(CC(O)=O)C(N1C(C(NC(CCCNC(N)=N)C(N2CCCC2C(NC(CC(C)C)C(NC(C(C)O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)CC3=CC=CC=C3 | ||
分子式 | C50H80N12O13 | 分子量 | 1057.24 |
溶解度 | ≥ 105.7mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.9459 mL | 4.7293 mL | 9.4586 mL |
5 mM | 0.1892 mL | 0.9459 mL | 1.8917 mL |
10 mM | 0.0946 mL | 0.4729 mL | 0.9459 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet